Clinical Value of Contrast-Enhanced Harmonic Endoscopic Ultrasonography in the Differential Diagnosis of Pancreatic and Gallbladder Masses by 諛뺤듅�슦 et al.
80  Copyright © 2018 Korean Society of Gastrointestinal Endoscopy 
ORIGINAL ARTICLE
Clin Endosc  2018;51:80-88
https://doi.org/10.5946/ce.2017.044
Print ISSN 2234-2400 • On-line ISSN 2234-2443
Clinical Value of Contrast-Enhanced Harmonic Endoscopic 
Ultrasonography in the Differential Diagnosis of Pancreatic and 
Gallbladder Masses 
Galam Leem, Moon Jae Chung, Jeong Youp Park, Seungmin Bang, Si Young Song, Jae Bock Chung and Seung Woo Park
Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
Background/Aims: Recent studies have revealed that contrast-enhanced harmonic endoscopic ultrasonography (CEH-EUS) is 
beneficial in the differential diagnosis of malignant neoplasms of the pancreas and gallbladder from benign masses, in terms of 
the evaluation of microvasculature and real-time perfusion. In this study, we aimed to prove the clinical value of CEH-EUS in the 
differential diagnosis of pancreatic and gallbladder masses by direct comparison with that of conventional EUS.
Methods: We reviewed the sonographic images and medical information of 471 patients who underwent conventional EUS and 
CEH-EUS for the diagnosis of pancreatic and gallbladder masses at a single medical center (Severance Hospital, Seoul, Korea) 
between March 2010 and March 2016.
Results: The enhancement pattern of CEH-EUS of the pancreatic solid masses showed higher sensitivity and specificity in 
differentiating pancreatic adenocarcinoma and neuroendocrine tumors (82.0% and 87.9% for pancreatic adenocarcinoma and 81.1% 
and 90.9% for neuroendocrine tumors, respectively), and the area under the receiver operating characteristic curves was higher 
than that of conventional EUS. The enhancement texture of CEH-EUS of the gallbladder masses showed a higher sensitivity in 
differentiating malignant masses than that of conventional EUS; however, the difference between the areas under the receiver operating 
characteristic curves was not statistically significant.
Conclusions: CEH-EUS can complement conventional EUS in the diagnosis of pancreatic and gallbladder masses, in terms of the 
limitations of the latter. Clin Endosc  2018;51:80-88
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IntRoDUCtIon
According to the statistical research announced by the 
Ministry of Health and Welfare Korea in March 2015, the 
crude incidence rate of pancreatic cancer and gallbladder 
cancer has increased gradually since 1999: from 6.4/100,000 
to 10.2/100,000 (pancreatic cancer) and from 5.5/100,000 to 
10.7/100,000 (gallbladder cancer). Compared with those of 
other digestive tract cancers, their 5-year survival rates are rel-
atively low: 8.8% and 28.3%, respectively. Therefore, early de-
tection of these cancers and distinguishing them from benign 
masses are gaining importance.
Endoscopic ultrasonography (EUS) is widely used in di-
agnosing pancreatic and gallbladder diseases because of its 
higher spatial resolution than other imaging methods.1-4 How-
ever, EUS is limited by its inability to evaluate hemodynamics 
and vascularity. Therefore, many attempts have been made to 
complement these limitations, such as the use of Doppler EUS 
and contrast-enhanced EUS.5-10 Doppler EUS is limited in dy-
namic perfusion imaging and cannot depict very slow-flow-
ing microscopic vessels and parenchymal perfusion.11,12 In 
contrast, contrast-enhanced harmonic (CEH) technology 
allows real-time perfusion imaging without Doppler-related 
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artifacts,11,12 and evaluation of both blood flow in small vessels 
(2 or 3 mm in minimum diameter) and parenchymal micro-
vasculature.13
Recently, CEH-EUS has been used to characterize solid 
pancreatic cancer and gastrointestinal stromal tumors.14,15 Ul-
trasound contrast agents consist of gas microbubbles covered 
by the shell of a biocompatible material, such as a protein, 
lipid, or polymer.16 Until recently, contrast-enhanced imag-
ing techniques for EUS were impossible to develop because 
all available echo-endoscope transducers were too small to 
produce sufficient acoustic power for CEH imaging using 
first-generation ultrasound contrast agents.16,17 However, sec-
ond-generation ultrasound contrast agents, such as SonoVue 
(Bracco Inc., Milan, Italy), Definity (Lantheus Medical Imag-
ing, North Billerica, MA, USA), and Sonazoid (Daiichi-Sankyo, 
Tokyo, Japan), are composed of stabilized microbubbles con-
taining perfluorocarbons or sulfur hexafluoride, an echogenic 
and poorly soluble gas.16-18 They are markedly improved in 
peripheral circulation.18 These second-generation ultrasound 
contrast agents produce harmonic signals at a lower acoustic 
power and are suitable for CEH-EUS imaging.15
A recent meta-analysis on contrast-enhanced EUS that an-
alyzed reports on both contrast-enhanced Doppler and CEH-
EUS showed that this method can differentially diagnose 
pancreatic adenocarcinomas with a pooled sensitivity and 
specificity of 94% and 89%, respectively.19 Moreover, for gall-
bladder neoplasms, a retrospective study on the use of CEH-
EUS for differentiating gallbladder adenomas from cholesterol 
polyps showed that it was useful in differentially diagnosing 
gallbladder adenomas with a sensitivity and specificity of 
75.0% and 66.6%, respectively.20 These studies focused only on 
enhancement patterns for the differential diagnosis; however, 
we use more parameters than just enhancement or echoic pat-
terns when we actually perform EUS.
Therefore, we aimed to prove the clinical value of CEH-
EUS in the differential diagnosis of pancreatic and gallbladder 
solid masses using a multi-parameter analysis in this study.
MAtERIALS AnD MEtHoDS
Study design
We retrospectively reviewed the sonographic images and 
medical information of 471 patients who underwent con-
ventional EUS and CEH-EUS for the diagnosis of pancreatic 
and gallbladder masses at a single medical center (Severance 
Hospital, Seoul, Korea) between March 2010 and March 2016. 
All endoscopic sonographies were performed by five pancre-
atobiliary endoscopy specialists (SWP, SYS, SMB, MJC and 
JYP), and each image was reviewed by two of the endoscopic 
physicians and blindly reviewed by one medical doctor (GLL).
Ultrasonography equipment
A radial echo-endoscope developed for CEH-EUS (GF-
UE260; Olympus Medical Systems Co., Tokyo, Japan) and 
a low acoustic power setting (mechanical index: 0.2) were 
used. Ultrasonography image analysis was performed using 
an Aloka ProSound Alpha-10 system (Aloka Co., Tokyo, 
Japan). After fundamental B-mode EUS was used to inves-
tigate the masses, the setting was changed to the extended 
pure harmonic detection mode, which combines the filtered 
fundamental and second harmonic component frequencies 
with a transmitting frequency of 5–7.5 MHz. Thereafter, 2.5 
mL of the contrast agent was injected into the antecubital vein 
in a bolus fashion through a 20-gauge intravenous cannula, 
followed by flushing with 5 mL of normal saline. SonoVue 
(Bracco) was used for the contrast agents. One ampule (2.5 
mL) of SonoVue contains 25 mg lyophilized sulfur hexafluo-
ride powder. The vascular structures were assessed in real time 
by examining continuous 0–90-s images after contrast agent 
injection. Early enhancement patterns were shown from 30 to 
45 s of the arterial phase, and late enhancement patterns were 
shown from 60 to 120 s of the venous phase.
Ultrasonography image analysis
The echogenic patterns of conventional EUS were classified 
into four categories: anechoic, hypoechoic, isoechoic, and 
hyperechoic. For pancreatic solid masses, these echogenic 
patterns were defined by comparing them with those of the 
normal pancreatic parenchyma. For gallbladder masses, these 
echogenic patterns were defined by comparing them with 
those of the gallbladder wall. 
The enhancement patterns of CEH-EUS were classified into 
four categories: nonenhancement, hypoenhancement, isoen-
hancement, and hyperenhancement. These enhancement pat-
terns were also defined by comparing them with those of the 
normal pancreatic parenchyma (in pancreatic solid masses) 
and those of the gallbladder wall (in gallbladder masses).
Other parameters that could be described using the sono-
graphic images, such as duct dilatation, tumor size, tumor de-
marcation, tumor marginal irregularity, hypoechoic foci, and 
focal wall thickness, were obtained and used for the analysis.
Statistical analysis
All analyses were performed using the SPSS v. 20 (SPSS Inc., 
Chicago, IL, USA). First, we compared conventional EUS and 
CEH-EUS according to their sensitivities and specificities that 
were calculated depending on the EUS findings. Their dis-
crimination abilities were evaluated using the classification ta-
ble. Thereafter, we determined the statistically significant vari-
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ables and obtained the receiver operating characteristic (ROC) 
curve and area under the curve (AUC) using logistic regres-
sion with the other parameters. They were calibrated with the 
Hosmer-Lemeshow test. Using a pairwise comparison of the 
AUCs, the clinical value of CEH-EUS was determined. P<0.05 
was considered significant.
Patient population
Among the 471 patients reviewed, pancreatic masses were 
diagnosed in 279 patients and gallbladder masses in 192 pa-
tients. Among the 279 patients with pancreatic masses, 72 
patients with cystic neoplasm of the pancreas were excluded. 
Among the 192 patients with gallbladder masses, 47 patients 
with gallbladder sludge not enhanced on CEH-EUS were ex-
cluded in the analysis.
RESULtS
Patient characteristics
Table 1 shows the baseline characteristics of the patients 
with pancreatic solid masses and gallbladder masses. Their 
mean age was 58.7 and 55.9 years, respectively, and all patients 
underwent conventional EUS and CEH-EUS for diagnosis. 
Among the pancreatic solid masses, ductal adenocarcinoma 
was the most common (45.9%), followed by neuroendocrine 
tumor (27.5%) and mass-forming pancreatitis (11.1%). Among 
the gallbladder masses, cholesterol polyps were the most 
common (30.7%), followed by adenocarcinoma (18.2%) and 
adenoma (7.8%).
Pancreatic solid mass
Supplementary Table 1 shows the vascular enhancement 
patterns of all 207 cases on CEH-EUS. With confirmed patho-
logic diagnosis, we measured the sensitivity and specificity 
for ductal adenocarcinoma and neuroendocrine tumor as 
hypoenhancement and hyperenhancement on CEH-EUS. 
The sensitivity and specificity for ductal adenocarcinoma 
were 82.0% and 87.9%, respectively. Conversely, those for 
neuroendocrine tumor were 81.1% and 90.9%, respectively. 
Supplementary Table 2 shows the echogenic patterns of all 
207 cases on conventional EUS; both ductal adenocarcinoma 
Table 1. Patient Characteristics
Pancreatic solid mass (n=207) Gallbladder mass (n=145)
Age (mean±SD) 58.7±13.9 55.4±15.2
Sex (M/F) 110/97 (53.1%/46.9%) 58/87 (40.0%/60.0%)
Diagnostic modality n (%)
   EUS 207 (100) 145 (100)
   CT 205 (99.0) 84 (57.9)
   MRI 163 (78.7) 35 (24.1)
   PET-CT 144 (69.6) 42 (29.0)
Tumor size (mm) (mean±SD) 25.3±15.0 15.6±10.9
Tumor location n (%)
Head/uncinate 82 (39.6) Neck 22 (15.2)
Neck 25 (12.1) Fundus 51 (35.2)
Body 48 (23.2) Body 72 (49.6)
Tail 52 (25.1)
Pathology n (%)
DA 95 (45.9) N eoplasm (adenocarcinoma 
and adenoma)
48 (33.1)
NET 57 (27.5)
MFP 23 (11.1)
SPN 14 (6.8) Non neoplasm 97 (66.9)
Others 20 (9.7)
SD, standard deviation; EUS, endoscopic ultrasonography; CT, computed tomography; MRI, magnetic resonance imaging; PET-CT, posi-
tron emission tomography-computed tomography; DA, ductal adenocarcinoma; NET, neuroendocrine tumor; MFP, mass forming pancre-
atitis; SPN, solid pseudopapillary neoplasm.
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and neuroendocrine tumors were mostly hypoechoic, such 
that when we calculated their sensitivity and specificity, they 
showed a very low sensitivity and a relatively high specific-
ity: sensitivity and specificity of 49.0% and 93.3% for ductal 
adenocarcinoma and 26.6% and 60.0% for neuroendocrine 
tumors, respectively.
The diagnostic ability can be improved by considering the 
enhancement texture and echogenic texture together with the 
enhancement or echogenic pattern. When ductal adenocar-
cinoma was classified as having hypoenhancement and inho-
mogeneous patterns on CEH-EUS, the sensitivity and speci-
ficity were estimated as 85.7% and 89.4%, respectively. When 
ductal adenocarcinoma was classified as having hypoechoic 
and inhomogeneous patterns using conventional EUS, the 
sensitivity and specificity were estimated as 52.1% and 78.74%, 
respectively. When neuroendocrine tumors were classified 
as having hyperenhancement and homogeneous patterns 
using CEH-EUS, the sensitivity and specificity were 85.3% 
and 91.0%, respectively. When the tumors were classified as 
having hypoenhancement and homogeneous patterns using 
conventional EUS, the sensitivity and specificity were 52.1% 
and 84.9%, respectively.
Ductal adenocarcinoma
To evaluate the clinical value of CEH-EUS, we analyzed 
the enhancement patterns and echogenic patterns with other 
parameters that we obtained from EUS. To diagnose ductal 
adenocarcinoma using the sonographic images, we analyzed 
these parameters using logistic regression to determine which 
variables were statistically significant (Table 2). 
Table 2 shows that age, duct dilatation, tumor size, tumor 
demarcation, tumor marginal irregularity, hypoechoic pattern 
on conventional EUS, and hypoenhancement on CEH-EUS 
are significant factors in the univariate analysis. We created 
two groups and verified these factors using a multivariate 
analysis: one group with a hypoechoic pattern and the oth-
er with a hypoenhancement pattern. It revealed that age, 
hypoechoic pattern, duct dilatation, tumor size, and tumor 
marginal irregularity were statistically significant in the mul-
tivariate analysis of the conventional EUS setting; further, age, 
hypoenhancement pattern, duct dilatation, and tumor mar-
ginal irregularity were statistically significant in that of the 
CEH-EUS setting. Using logistic regression, we obtained the 
following predicted probability equations for each and their 
ROC curves (Fig. 1A). 
Predicted probability equation with conventional EUS: 1 / (1 
+ exp (-A)), where A = -7.888 + (0.052 × Age) + (2.770 × Hy-
poechoic) + (1.749 × Duct dilatation) + (0.028 × Tumor size) 
+ (-0.497 × Tumor demarcation) + (2.695 × Tumor marginal 
irregularity).
Predicted probability equation with CEH-EUS: 1 / (1 + exp 
(-A)), where A = -7.074 + (0.056 × Age) + (3.557 × Hypoen-
hancement) + (1.848 × Duct dilatation) + (0.016 × Tumor size) 
+ (-0.808 × Tumor demarcation) + (2.953 × Tumor marginal 
irregularity).
Using a pairwise comparison of the ROC curves for ductal 
adenocarcinoma, the difference between the areas under the 
ROC curves (AUROCs) was 0.0602, which was statistically 
significant (p=0.001).
When we analyzed the parameters from conventional EUS 
and CEH-EUS together, the enhancement pattern of CEH-
EUS was the single powerful parameter; thus, the echogenic 
pattern on conventional EUS lost its power and was no longer 
significant in the diagnosis.
Table 2. Univariate and Multivariate Analysis of Variables for Ductal Adenocarcinoma
Variables
Univariate
Multivariate
Conventional EUS CEH-EUS
odds ratio (95% CI) p-value odds ratio (95% CI) p-value odds ratio (95% CI) p-value
Age 1.049 (1.025–1.073) <0.001 1.053 (1.024–1.084) <0.001 1.058 (1.018–1.100) 0.004
Sex 0.785 (0.466–1.325) 0.365
Duct dilatation 6.657 (2.606–17.008) <0.001 5.748 (1.829–18.060 0.003 6.344 (1.470–27.379) 0.013
Tumor size 1.043 (1.021–1.065) <0.001 1.029 (1.003–1.056) 0.030 1.016 (0.984–1.049) 0.333
Tumor demarcation 3.442 (1.729–6.852) <0.001 0.608 (0.210–1.760) 0.359 0.446 (0.112–1.771) 0.251
T umor marginal  
irregularity
13.372 (6.782–26.366) <0.001 14.805 (5.859–37.408) <0.001 19.167 (5.678–64.705) <0.001
Hypoechoic 13.429 (1.732–104.144) 0.013 15.955 (1.167–218.136) 0.038
Hypoenhance 35.249 (16.155–76.912) <0.001 35.071 (12.261–100.315) <0.001
EUS, endoscopic ultrasonography; CEH-EUS, contrast-enhanced harmonic endoscopic ultrasonography; CI, confidence interval.
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Neuroendocrine tumor
With the same methods used for ductal adenocarcinoma, 
we repeated the analysis for neuroendocrine tumors (Table 3). 
As mentioned before, the sensitivity for neuroendocrine 
tumors with a hypoechoic pattern was too low. Therefore, 
the hypoechoic pattern was not statistically significant at this 
time. Duct dilatation, tumor size, tumor demarcation, tumor 
marginal irregularity, and hyperenhancement pattern were 
statistically significant in the univariate analysis.
Table 3 reveals the factors that were statistically significant 
in the multivariate analysis: duct dilatation, tumor size, and 
tumor marginal irregularity for conventional EUS and hyper-
enhancement pattern, tumor size, and tumor marginal irregu-
larity for CEH-EUS. Using logistic regression, we obtained the 
following predicted probability equations for each and their 
ROC curves (Fig. 1B). 
Predicted probability equation with conventional EUS: 1 / (1 
+ exp (-A)), where A = 0.952 + (0.171 × Hypoechoic) + (-2.374 
× Duct dilatation) + (-0.056 × Tumor size) + (-0.252 × Tumor 
demarcation) + (-2.594 × Tumor marginal irregularity).
Predicted probability equation with CEH-EUS: 1 / (1 + exp 
(-A)), where A = -0.259 + (3.287 × Hyperenhancement) + 
(-2.081 × Duct dilatation) + (-0.057 × Tumor size) + (-0.070 × 
Tumor demarcation) + (-1.699 × Tumor marginal irregularity).
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Fig. 1. Comparison of the receiver operating characteristic (ROC) curve with predicted probabilities from contrast-enhanced harmonic endoscopic ultrasonography 
(CEH-EUS) and conventional EUS. (A) For ductal adenocarcinoma. The area under the ROC curve for CEH-EUS is 0.949 (SE 0.0140) and that for conventional EUS 
is 0.889 (SE 0.0220). (B) For neuroendocrine tumors. The area under the ROC curve for CEH-EUS is 0.945 (SE 0.0145) and that for conventional EUS is 0.870 (SE 
0.0274).  
Table 3. Univariate and Multivariate Analysis of Variables for Neuroendocrine Tumor
Variables
Univariate
Multivariate
Conventional EUS CEH-EUS
odds ratio (95% CI) p-value odds ratio (95% CI) p-value odds ratio (95% CI) p-value
Age 0.986 (0.964–1.007) 0.195
Sex 1.635 (0.920–2.906) 0.094
Duct dilatation 0.069 (0.009–0.515) 0.009 0.093 (0.011–0.758) 0.026 0.125 (0.012–1.292) 0.081
Tumor size 0.922 (0.889–0.955) <0.001 0.946 (0.914–0.978) 0.001 0.945 (0.908–0.983) 0.005
Tumor demarcation 0.182 (0.062–0.533) 0.002 0.777 (0.193–3.135) 0.723 0.933 (0.180–4.826) 0.934
T umor marginal  
irregularity
0.047 (0.014–0.158) <0.001 0.075 (0.020–0.281) <0.001 0.183 (0.040–0.840) 0.029
Hypoechoic 0.543 (0.184–1.600) 0.268 1.186 (0.349–4.035) 0.784
Hyperenhance 43.000 (17.826–103.722) <0.001 26.771 (9.633–74.397) <0.001
EUS, endoscopic ultrasonography; CEH-EUS, contrast-enhanced harmonic endoscopic ultrasonography; CI, confidence interval.
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Using a pairwise comparison of the ROC curves for neu-
roendocrine tumor, the difference between the AUROCs was 
0.0744, which was statistically significant (p=0.0014).
Gallbladder mass
First, we focused on the differentiation of malignant masses 
from benign masses. There were 35 cases of malignant masses 
consisting of adenocarcinomas and carcinosarcomas and 110 
cases of benign masses consisting of adenomas, adenomyo-
mas, adenomyomatosis, cholesterol polyps, fundic gland pol-
yps, pyloric gland polyps, hyperplastic polyps, cholesterolosis, 
and cholecystitis.
Unlike the pancreatic solid masses, the gallbladder malig-
nant masses did not show any specific enhancement or echo-
genic patterns (Supplementary Table 3). Therefore, we used 
the echogenic and vascular enhancement textures (homoge-
nous or inhomogeneous) to differentiate the malignant mass-
es. Malignant masses tended to be shown inhomogeneously 
both on conventional EUS and CEH-EUS (Supplementary 
Table 4). When we diagnosed the malignant masses as hav-
ing an inhomogeneous texture using conventional EUS, the 
sensitivity and specificity were 77.1% and 82.7%, respectively. 
Using CEH-EUS, the sensitivity increased up to 97.1%, and 
the specificity decreased to 55.5%. Regarding the importance 
of the sensitivity of the diagnosis tool for malignancy, CEH-
EUS showed a competitive value.
For further evaluation of the value of CEH-EUS, we ana-
lyzed the texture patterns with other parameters, including 
sex, age, hypoechoic foci, tumor size, multi-lobulated appear-
ance, and number of lesions, using logistic regression (Table 4). 
Table 4 shows that age, hypoechoic foci, tumor size, 
multi-lobulated appearance, inhomogeneous echogenicity, 
and inhomogeneous enhancement are significant in the 
univariate analysis. We separated them into two groups 
(conventional EUS and CEH-EUS) and verified these factors 
using a multivariate analysis. In the conventional EUS group, 
hypoechoic foci, tumor size, and inhomogeneous texture on 
conventional EUS were significant. In the CEH-EUS group, 
hypoechoic foci, tumor size, and inhomogeneous texture on 
CEH-EUS were also significant. 
To compare the two groups directly, we obtained the fol-
lowing predicted probability equations for each and their 
ROC curves (Fig. 2) as we did for the pancreatic solid masses.
Predicted probability equation with conventional EUS: 1 / (1 
+ exp (-A)), where A = -4.137 + (2.483 × Hypoechoic foci) + 
(0.082 × Mass size) + (1.426 × Inhomogeneous texture in con-
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Fig. 2. Comparison of the receiver operating characteristic (ROC) curve with 
predicted probabilities from contrast-enhanced harmonic endoscopic ultraso-
nography (CEH-EUS) and conventional EUS for gallbladder malignant masses. 
The area under the ROC curve for CEH-EUS is 0.939 (SE 0.0218) and that for 
conventional EUS is 0.912 (SE 0.0331).
Table 4. Univariate and Multivariate Analysis of Variables for Gallbladder Malignant Masses
Variables
Univariate
Multivariate
Conventional EUS CEH-EUS
odds ratio (95% CI) p-value odds ratio (95% CI) p-value odds ratio (95% CI) p-value
Sex 1.263 (0.577–2.762) 0.559
Age 1.093 (1.052–1.136) <0.001 1.049 (0.998–1.103) 0.060 1.056 (0.998–1.117) 0.058
Hypoechoic foci 27.818 (10.097–76.643) <0.001 8.273 (2.223–30.785) 0.002 9.816 (2.777–34.700) <0.001
Tumor size 1.114 (1.066–1.165) <0.001 1.062 (1.002–1.124) 0.041 1.086 (1.018–1.158) 0.013
Multi-lobulated 3.185 (1.419–7.149) 0.005 2.563 (0.710–9.255) 0.151 1.332 (0.344–5.163) 0.678
Multiple lesions <0.001 0.998
C onvEUS inhomogeneous 16.164 (6.371–41.012) <0.001 4.166 (1.163–14.918) 0.028
C EH-EUS inhomogeneous 42.327 (5.593–320.290) <0.001 25.681 (2.579–255.689) 0.006
EUS, endoscopic ultrasonography; CEH-EUS, contrast-enhanced harmonic endoscopic ultrasonography; CI, confidence interval.
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ventional EUS).
Predicted probability equation with CEH-EUS: 1 / (1 + exp 
(-A)), where A = -6.760 + (2.718 × Hypoechoic foci) + (0.104 × 
Mass size) + (3.457 × Inhomogeneous texture in CEH-EUS).
Using a pairwise comparison of the ROC curves for malig-
nant gallbladder masses, the difference between the AUROCs 
was 0.0270, which was not statistically significant (p=0.2383).
Thereafter, we further expanded our study to determine the 
clinical value of CEH-EUS in the differentiation of the surgi-
cal indication of gallbladder masses. We classified all gallblad-
der masses into two groups: neoplasm group, which requires 
surgery, and non-neoplasm group, which does not require 
surgery. The neoplasm group consisted of adenomas, adeno-
carcinomas, and carcinosarcomas, while the non-neoplasm 
group consisted of the other masses. 
As shown in the malignant mass evaluation, the neoplasm 
and non-neoplasm groups also did not show any specific 
echoic or enhancement patterns. Therefore, we categorized 
them according to their vascular and echogenic textures: ho-
mogeneous or inhomogeneous. The neoplasms showed most-
ly an inhomogeneous enhancement pattern (80%); however, 
the non-neoplasms were not characterized by CEH-EUS. The 
sensitivity and specificity for the neoplasms with an inhomo-
geneous enhancement pattern were only 40.4% and 85.5%, 
respectively. Conversely, the non-neoplasms on conventional 
EUS at this time mostly showed a homogenous echoic pat-
tern; however, the neoplasms did not show a specific pattern. 
The sensitivity and specificity for the neoplasms with an inho-
mogeneous echoic pattern were 60.9% and 82.0%, respectively, 
which imply that conventional EUS is still inappropriate as a 
diagnostic tool.
When analyzed with other parameters, only age and hy-
poechoic foci were the only statistically significant variables in 
both groups (Supplementary Table 5). This reveals that EUS 
is not enough in determining the necessity of surgery in gall-
bladder masses.
DISCUSSIon
To prove the clinical value of CEH-EUS in the differential 
diagnosis of pancreatic and gallbladder solid masses, we de-
signed the study with following two aims: to compare the (1) 
sensitivity and specificity and (2) the ROC curves in the diag-
nosis. In this study, we proved the superiority of CEH-EUS in 
the differential diagnosis of pancreatic masses over conven-
tional EUS with higher sensitivity, specificity, and AUROC 
for ductal adenocarcinoma and neuroendocrine tumor. For 
gallbladder masses, CEH-EUS showed its powerful value with 
a high AUROC in diagnosing malignant masses; however, its 
superiority over conventional EUS was not proven.
In the comparison of the diagnostic ability of the enhance-
ment pattern and echogenic pattern of the pancreatic solid 
masses, the enhancement pattern showed higher sensitivity 
(82.0%) and specificity (87.9%) for ductal adenocarcinoma 
than the echogenic pattern (relatively low sensitivity [49.0%] 
and high specificity [93.3%]). Previous studies revealed that 
only with the enhancement pattern can the sensitivity and 
specificity be improved up to 95%.1,3,4 However, it was not that 
precise in the actual clinical field. To improve the sensitivity 
and specificity, we considered the enhancement and echo-
genic textures together. Most cases of ductal adenocarcinoma 
showed an inhomogeneous texture; thus, considering the in-
homogeneous texture together with the enhancement pattern 
could improve the diagnostic ability. When we classified duc-
tal adenocarcinoma as having hypoenhancement and inho-
mogeneous patterns using CEH-EUS, the sensitivity and spec-
ificity increased up to 85.7% and 89.4%, respectively. When 
ductal adenocarcinoma was classified as having hypoechoic 
and inhomogeneous patterns using conventional EUS, the 
sensitivity and specificity increased up to 52.1% and 78.74%, 
respectively. In the neuroendocrine tumors, the changes were 
more dramatic. When the neuroendocrine tumor was clas-
sified as having hyperenhancement and homogeneous pat-
terns using CEH-EUS, the sensitivity and specificity changed 
from 81.1% to 85.3% and from 90.9% to 91.0%, respectively, 
compared with that classified as having a hyperenhancement 
pattern only. When the neuroendocrine tumor was classified 
as having hypoenhancement and homogeneous patterns us-
ing conventional EUS, the sensitivity and specificity changed 
from 26.6% to 52.1% and from 60.0% to 84.9%, respectively, 
compared with that classified as having a hyperenhancement 
pattern only.
After considering the texture with echogenic and enhance-
ment patterns, CEH-EUS was still better in diagnosing ductal 
adenocarcinoma and neuroendocrine tumor than conven-
tional EUS; however, the sensitivity and specificity were not 
as high as those in previous studies that reported nearly 95% 
for both. Therefore, we analyzed the parameters that physi-
cians actually consider in the diagnosis together. In the logistic 
regression, the AUROC of CEH-EUS was 0.949 for ductal 
adenocarcinoma and 0.945 for neuroendocrine tumor. Con-
sidering that a model with AUC >0.75 is usually considered a 
powerful predictable model, we can conclude that the predic-
tive model with the parameters of CEH-EUS is very powerful 
and rather precise. Although the model was not validated 
externally and the total patient numbers were not enough to 
create a scoring model, it can be concluded that the model 
is powerful in diagnosing ductal adenocarcinoma and neu-
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roendocrine tumors precisely using the parameters of CEH-
EUS. The calculated AUROC of conventional EUS for ductal 
adenocarcinoma and neuroendocrine tumor was 0.890 and 
0.871, respectively, indicating that it is still a useful predictive 
model but is less powerful than CEH-EUS, with a statistical 
significance.
To prove the clinical value of CEH-EUS, we next present 
two example cases. The first case involves a 34-year-old male 
patient experiencing abdominal pain for 1 month. He had 
no family history of pancreatic cancer, and the levels of the 
tumor markers carcinoembryonic antigen and CA19-9 were 
within the reference ranges. On computed tomography (CT) 
scan, a 15-mm pancreatic mass was found. Considering his 
age, tumor marker level, and tumor size, the tumor was less 
likely pancreatic cancer, but rather possibly pancreatitis or 
another benign disease. He underwent CEH-EUS, which 
showed a hypoenhancement pattern, dilated pancreatic duct, 
and poorly demarcated and rough mass margin. Using the 
probability equation we created, his pancreatic lesion had a 
probability rate of 93.2% for ductal adenocarcinoma and 0.7% 
for neuroendocrine tumor. Therefore, he underwent surgery, 
and the pathology revealed pancreatic ductal adenocarcino-
ma. The second case is that of a 78-year-old female patient 
who was also experiencing abdominal pain for 2 weeks. She 
had no family history of pancreatic cancer, and the tumor 
marker levels were also in the reference ranges. On CT scan, 
a 15-mm pancreatic mass was found. Unlike the previous 
patient, this patient was old enough to raise suspicion for pan-
creatic cancer. On CEH-EUS, she had a hyperenhancement 
pattern, normal pancreatic duct, and well-demarcated and 
smooth mass margin. Using the probability equation we cre-
ated, her pancreatic lesion had a probability rate of 7.8% for 
ductal adenocarcinoma and 89.8% for neuroendocrine tumor. 
Because of her old age, we planned surgical resection, and the 
pathology revealed a neuroendocrine tumor.
These two patients had similar pancreatic mass sizes. 
However, some features on CEH-EUS were different, and 
despite their unmatched age, the probability equation proved 
its precise ability of predicting ductal adenocarcinoma and 
neuroendocrine tumor. This would provide physicians more 
information on the diagnosis of pancreatic masses and help 
them in the treatment decision-making.
When we classified the malignant gallbladder masses with 
an enhancement pattern as what we did for the pancreatic 
solid masses, they did not have any specific enhancement 
pattern. This is similar to the result of a previous study.20 
Therefore, we used the echogenic and vascular enhancement 
textures (inhomogeneous or homogeneous) for the diagnosis 
of the gallbladder masses and showed that an inhomogeneous 
enhancement texture on CEH-EUS could be a single powerful 
diagnostic parameter for malignant masses with a sensitivity 
of 97.1%. Analyzed with other parameters from ultrasonogra-
phy, CEH-EUS showed its clinical value with an AUROC of 
0.939, but did not prove its superiority over conventional EUS 
(p=0.2383). 
Expanding the study into the differential diagnosis of neo-
plasms, CEH-EUS still was not superior to conventional EUS. 
This would be because of the different characteristics between 
adenomas and adenocarcinomas; thus, grouping these two 
pathologies in the same group did not profit EUS. 
There were some limitations in this study. This study per-
formed a retrospective data analysis, and we did not measure 
the degree of enhancement quantitatively. However, the 
results were sufficient to prove the superiority of CEH-EUS 
in the differential diagnosis of pancreatic solid masses over 
conventional EUS. With the high sensitivity of the enhance-
ment texture of malignant gallbladder masses, it could be 
useful in screening such masses. In addition, we can diagnose 
malignant masses with a high probability (AUROC of 0.939), 
if we consider the enhancement texture, size, and hypoechoic 
foci of the mass on CEH-EUS. Although the superiority was 
not statistically significant, CEH-EUS still shows its powerful 
clinical value. 
ConCLUSIonS
Previously and widely used conventional EUS is limited 
in the evaluation of the microvasculature of diseases in the 
pancreas and gallbladder. In this study, we suggest that CEH-
EUS has a high clinical value in the differential diagnosis of 
pancreatic masses and malignant gallbladder masses; thus, it 
can supplement the limitations of conventional EUS. Further 
studies that would consider the quantitation of enhancement 
and other diagnostic features are needed to overcome these 
limitations.
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